| Dallas Rose Lawry, DNP, FNP-C | |
|
1200 Garden View Rd, Encinitas, CA 92024-2477 | |
| (760) 536-7700 | |
| (760) 536-7698 |
| Full Name | Dallas Rose Lawry |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 1200 Garden View Rd, Encinitas, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871262345 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 95017937 (California) | Secondary |
| 363L00000X | Nurse Practitioner | 95017937 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Uc San Diego Health Hillcrest - Hillcrest Med Ctr | San diego, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of California | 3577476761 | 1692 |
News Archive
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.
A new study has been published on the medRxiv* preprint server, which focuses on the effectiveness of the BNT162b2 vaccine by studying the susceptibility of a vaccinated individual to infection. The researchers have also studied the effect of the vaccine on virus transmission.
Watson Pharmaceuticals, Inc., today confirmed that the United States District Court for the District of Delaware has ruled that Watson's generic version of Fentora® (fentanyl buccal tablets C-II) infringes United States Patent No. 6,264,981 (the '981 Patent). The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal.
A powerful new tool available at the University of Virginia Health System offers treatment to patients with some of the most challenging cancers of the head and neck.
› Verified 5 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376646869 PECOS PAC ID: 3577476761 Enrollment ID: O20031112000695 |
News Archive
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.
A new study has been published on the medRxiv* preprint server, which focuses on the effectiveness of the BNT162b2 vaccine by studying the susceptibility of a vaccinated individual to infection. The researchers have also studied the effect of the vaccine on virus transmission.
Watson Pharmaceuticals, Inc., today confirmed that the United States District Court for the District of Delaware has ruled that Watson's generic version of Fentora® (fentanyl buccal tablets C-II) infringes United States Patent No. 6,264,981 (the '981 Patent). The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal.
A powerful new tool available at the University of Virginia Health System offers treatment to patients with some of the most challenging cancers of the head and neck.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dallas Rose Lawry, DNP, FNP-C Po Box 232410, San Diego, CA 92193-2410 Ph: () - | Dallas Rose Lawry, DNP, FNP-C 1200 Garden View Rd, Encinitas, CA 92024-2477 Ph: (760) 536-7700 |
News Archive
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.
A new study has been published on the medRxiv* preprint server, which focuses on the effectiveness of the BNT162b2 vaccine by studying the susceptibility of a vaccinated individual to infection. The researchers have also studied the effect of the vaccine on virus transmission.
Watson Pharmaceuticals, Inc., today confirmed that the United States District Court for the District of Delaware has ruled that Watson's generic version of Fentora® (fentanyl buccal tablets C-II) infringes United States Patent No. 6,264,981 (the '981 Patent). The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal.
A powerful new tool available at the University of Virginia Health System offers treatment to patients with some of the most challenging cancers of the head and neck.
› Verified 5 days ago